The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol

BackgroundThe continuing uncertainty around Brexit has caused concern in the pharmaceutical industry and among health care professionals and patients. The exact consequences of Brexit on the pharmaceutical supply chain in the United Kingdom will depend on whether a deal is reached and what it entail...

Full description

Bibliographic Details
Main Authors: Milne-Ives, Madison, Lam, Ching, van Velthoven, Michelle, Meinert, Edward
Format: Article
Language:English
Published: JMIR Publications 2020-09-01
Series:JMIR Research Protocols
Online Access:http://www.researchprotocols.org/2020/9/e17684/
_version_ 1828937889976680448
author Milne-Ives, Madison
Lam, Ching
van Velthoven, Michelle
Meinert, Edward
author_facet Milne-Ives, Madison
Lam, Ching
van Velthoven, Michelle
Meinert, Edward
author_sort Milne-Ives, Madison
collection DOAJ
description BackgroundThe continuing uncertainty around Brexit has caused concern in the pharmaceutical industry and among health care professionals and patients. The exact consequences of Brexit on the pharmaceutical supply chain in the United Kingdom will depend on whether a deal is reached and what it entails, but it is likely to be affected by the withdrawal of the United Kingdom from the European Union. Regulatory issues and delays in supply have the potential to negatively affect the ability of UK residents to receive an adequate and timely supply of necessary medicines. ObjectiveThe purpose of this protocol is to provide an overview and critical analysis of current perspectives on the effect of Brexit on the UK pharmaceutical supply chain. MethodsThe PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines will be used to structure this protocol. A systematic search of MEDLINE, EMBASE, PsycINFO, Healthcare Management Information Consortium (HMIC), Cochrane, Web of Science, Business Source Complete, EconLit, and Economist Intelligence Unit will be conducted, as well as a Google and Nexis.UK search for grey literature such as reports, opinion pieces, and press releases. Two reviewers will independently screen the titles and abstracts of identified references and select studies according to the eligibility criteria. Any discrepancies will then be discussed and resolved. One reviewer will extract data from the included studies into a standardized form, which will be validated by a second reviewer. Risk of bias will be assessed using the Cochrane Collaboration Risk of Bias tool for any randomized controlled trials; quality will be assessed using the relevant Critical Appraisal Skills Programme (CASP) checklists; and grey literature will be assessed using the Authority, Accuracy, Coverage, Objectivity, Date, Significance (AACODS) checklist. Outcomes include the agreement between sources on the potential, likelihood, and severity of the consequences of Brexit on the UK pharmaceutical supply chain. ResultsResults will be included in the scoping review, which will be published in 2020. ConclusionsThis scoping review will summarize the currently expected consequences of Brexit on the UK pharmaceutical supply chain. International Registered Report Identifier (IRRID)PRR1-10.2196/17684
first_indexed 2024-12-14T02:32:28Z
format Article
id doaj.art-ca79bba775c546db8412ff8553b6b5d1
institution Directory Open Access Journal
issn 1929-0748
language English
last_indexed 2024-12-14T02:32:28Z
publishDate 2020-09-01
publisher JMIR Publications
record_format Article
series JMIR Research Protocols
spelling doaj.art-ca79bba775c546db8412ff8553b6b5d12022-12-21T23:20:13ZengJMIR PublicationsJMIR Research Protocols1929-07482020-09-0199e1768410.2196/17684The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review ProtocolMilne-Ives, MadisonLam, Chingvan Velthoven, MichelleMeinert, EdwardBackgroundThe continuing uncertainty around Brexit has caused concern in the pharmaceutical industry and among health care professionals and patients. The exact consequences of Brexit on the pharmaceutical supply chain in the United Kingdom will depend on whether a deal is reached and what it entails, but it is likely to be affected by the withdrawal of the United Kingdom from the European Union. Regulatory issues and delays in supply have the potential to negatively affect the ability of UK residents to receive an adequate and timely supply of necessary medicines. ObjectiveThe purpose of this protocol is to provide an overview and critical analysis of current perspectives on the effect of Brexit on the UK pharmaceutical supply chain. MethodsThe PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines will be used to structure this protocol. A systematic search of MEDLINE, EMBASE, PsycINFO, Healthcare Management Information Consortium (HMIC), Cochrane, Web of Science, Business Source Complete, EconLit, and Economist Intelligence Unit will be conducted, as well as a Google and Nexis.UK search for grey literature such as reports, opinion pieces, and press releases. Two reviewers will independently screen the titles and abstracts of identified references and select studies according to the eligibility criteria. Any discrepancies will then be discussed and resolved. One reviewer will extract data from the included studies into a standardized form, which will be validated by a second reviewer. Risk of bias will be assessed using the Cochrane Collaboration Risk of Bias tool for any randomized controlled trials; quality will be assessed using the relevant Critical Appraisal Skills Programme (CASP) checklists; and grey literature will be assessed using the Authority, Accuracy, Coverage, Objectivity, Date, Significance (AACODS) checklist. Outcomes include the agreement between sources on the potential, likelihood, and severity of the consequences of Brexit on the UK pharmaceutical supply chain. ResultsResults will be included in the scoping review, which will be published in 2020. ConclusionsThis scoping review will summarize the currently expected consequences of Brexit on the UK pharmaceutical supply chain. International Registered Report Identifier (IRRID)PRR1-10.2196/17684http://www.researchprotocols.org/2020/9/e17684/
spellingShingle Milne-Ives, Madison
Lam, Ching
van Velthoven, Michelle
Meinert, Edward
The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
JMIR Research Protocols
title The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
title_full The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
title_fullStr The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
title_full_unstemmed The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
title_short The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
title_sort impact of brexit on the pharmaceutical supply chain of the united kingdom scoping review protocol
url http://www.researchprotocols.org/2020/9/e17684/
work_keys_str_mv AT milneivesmadison theimpactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT lamching theimpactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT vanvelthovenmichelle theimpactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT meinertedward theimpactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT milneivesmadison impactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT lamching impactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT vanvelthovenmichelle impactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol
AT meinertedward impactofbrexitonthepharmaceuticalsupplychainoftheunitedkingdomscopingreviewprotocol